If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
HEPATOLOGY
Alexion supplement • emjreviews.com
INSIDE
The Role of Sebelipase Alfa
in Treating Lysosomal Acid
Lipase Deficiency (LAL-D)
THE ROLE OF SEBELIPASE ALFA IN TREATING
LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D)
Summary of presentations from the Alexion-Sponsored
Educators Forum on LAL-D, held in Frankfurt, Germany,
on 29th and 30th October 2015
Speakers
Florian Abel,1 Barbara K. Burton,2 Brett Billmeyer3
1. Medical Affairs Europe, Middle-East, Africa, Asia-Pacific, Alexion Pharmaceuticals
2. Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
3. Afton, Minnesota, USA
Disclosure: Dr Abel is a full-time employee of Alexion Pharmaceuticals. In the past 3 years, he has also
been employed by Synageva BioPharma and Daiichi Sankyo Europe. Prof Burton has received
HEPATOLOGY Alexion supplement • emjreviews.com
THE ROLE OF SEBELIPASE ALFA IN TREATING LYSOSOMAL
Lysosomal Acid Lipase Deficiency: A Progressive Di
LIVER ABNORMALITIES HEPATIC STEATOSIS (microvesic
abnormalities (87% of patients).1 In the liver, L
Sebelipase alfa was approved in the Europea
Key results: infants (LAL-CL03)15 LAL-CL03 was
The implications of this study are
Med. 2015. doi: 10.1038/gim.2015.108. [Epub